1. Home
  2. ANAB vs ANGX Comparison

ANAB vs ANGX Comparison

Compare ANAB & ANGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • ANGX
  • Stock Information
  • Founded
  • ANAB 2005
  • ANGX 2013
  • Country
  • ANAB United States
  • ANGX United States
  • Employees
  • ANAB N/A
  • ANGX N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • ANGX Movies/Entertainment
  • Sector
  • ANAB Health Care
  • ANGX Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • ANGX Nasdaq
  • Market Cap
  • ANAB 1.0B
  • ANGX 964.0M
  • IPO Year
  • ANAB 2017
  • ANGX N/A
  • Fundamental
  • Price
  • ANAB $38.47
  • ANGX $6.57
  • Analyst Decision
  • ANAB Buy
  • ANGX Strong Buy
  • Analyst Count
  • ANAB 12
  • ANGX 1
  • Target Price
  • ANAB $63.30
  • ANGX $14.00
  • AVG Volume (30 Days)
  • ANAB 364.4K
  • ANGX 497.3K
  • Earning Date
  • ANAB 11-04-2025
  • ANGX 01-01-0001
  • Dividend Yield
  • ANAB N/A
  • ANGX N/A
  • EPS Growth
  • ANAB N/A
  • ANGX N/A
  • EPS
  • ANAB N/A
  • ANGX N/A
  • Revenue
  • ANAB $169,467,000.00
  • ANGX $186,233,863.00
  • Revenue This Year
  • ANAB $37.52
  • ANGX $197.90
  • Revenue Next Year
  • ANAB N/A
  • ANGX $19.95
  • P/E Ratio
  • ANAB N/A
  • ANGX N/A
  • Revenue Growth
  • ANAB 196.42
  • ANGX N/A
  • 52 Week Low
  • ANAB $12.21
  • ANGX $3.77
  • 52 Week High
  • ANAB $40.96
  • ANGX $20.39
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 72.78
  • ANGX N/A
  • Support Level
  • ANAB $34.22
  • ANGX N/A
  • Resistance Level
  • ANAB $37.08
  • ANGX N/A
  • Average True Range (ATR)
  • ANAB 2.03
  • ANGX 0.00
  • MACD
  • ANAB -0.18
  • ANGX 0.00
  • Stochastic Oscillator
  • ANAB 68.07
  • ANGX 0.00

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About ANGX Angel Studios Inc. Class A Common Stock

Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.

Share on Social Networks: